Biomaterial Database

[Bronchial asthma: progress in diagnosis and treatments. Topics: IV. Subtype/particular type/comorbidities; 4. Aspirin-exacerbated respiratory disease (AERD)]. 2013

Masami Taniguchi

National Hospital Organization Sagamihara National Hospital Clinical Research Center, Japan.

UI	MeSH Term	Description	Entries
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001241	Aspirin	The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)	Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D001249	Asthma	A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	Asthma, Bronchial,Bronchial Asthma,Asthmas
D015897	Comorbidity	The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
D016896	Treatment Outcome	Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.	Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D055963	Asthma, Aspirin-Induced	Asthmatic adverse reaction (e.g., BRONCHOCONSTRICTION) to conventional NSAIDS including aspirin use.	Aspirin Induced Asthma,Aspirin-Induced Asthma,Aspirin-Induced Asthma Syndrome,Asthma, NSAID-induced,NERD NSAID-Exacerbated Respiratory Disease,NSAID-Exacerbated Respiratory Disease,Aspirin Induced Asthma Syndrome,Aspirin Induced Asthmas,Aspirin-Induced Asthma Syndromes,Aspirin-Induced Asthmas,Asthma Syndrome, Aspirin-Induced,Asthma Syndromes, Aspirin-Induced,Asthma, Aspirin Induced,Asthma, NSAID induced,Asthmas, Aspirin Induced,Asthmas, Aspirin-Induced,Asthmas, NSAID-induced,Disease, NSAID-Exacerbated Respiratory,Diseases, NSAID-Exacerbated Respiratory,Induced Asthma, Aspirin,Induced Asthmas, Aspirin,NERD NSAID Exacerbated Respiratory Disease,NSAID Exacerbated Respiratory Disease,NSAID-Exacerbated Respiratory Diseases,NSAID-induced Asthma,NSAID-induced Asthmas,Respiratory Disease, NSAID-Exacerbated,Respiratory Diseases, NSAID-Exacerbated,Syndrome, Aspirin-Induced Asthma,Syndromes, Aspirin-Induced Asthma